Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421908 | 0.80 | DGAT1 (0.35) | CA12CA2CA14CYP2D6DGAT1 | |
| SCHEMBL5229803 | 0.77 | MGAM (0.33) | GAA | |
| SCHEMBL28346521 | 0.74 | TDP1 (0.43) | CA12CA2CA14CA1CA9 | |
| SCHEMBL20572704 | 0.74 | CA2 (0.40) | CA12CA2CA14CA1CA9 | |
| SCHEMBL1949382 | 0.74 | CA12 (0.40) | CA12CA2CA14CA1CA9 | |
| SCHEMBL28206658 | 0.73 | CA2 (0.39) | CA12CA2CA14CA1CA9 | |
| SCHEMBL28363958 | 0.72 | TSHR (0.54) | CA12CA2CA14CA1CA9 | |
| SCHEMBL28691228 | 0.72 | TSHR (0.33) | GAA | |
| SCHEMBL18985138 | 0.72 | TDP1 (0.44) | CA12CA2CA14CA1CA9 | |
| SCHEMBL377844 | 0.72 | ALDH1A1 (0.41) | CA12CA2CA14CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655643-B2 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2010-02-02 | — | — | US | disclosed |
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | NOD2, AHR, BCL2 | CA12 4820/4885CA2 4793/4885CA14 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.